Influenza vaccination in the time of COVID-19: A national U.S. survey of adults

dc.contributor.authorSturm, Lynne
dc.contributor.authorKasting, Monica L.
dc.contributor.authorHead, Katharine J.
dc.contributor.authorHartsong, Jane A.
dc.contributor.authorZimet, Gregory D.
dc.contributor.departmentPediatrics, School of Medicineen_US
dc.date.accessioned2021-04-23T18:10:32Z
dc.date.available2021-04-23T18:10:32Z
dc.date.issued2021
dc.descriptionThis article is made available for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.en_US
dc.description.abstractIntroduction Decisions about influenza vaccination for fall-winter 2020 were made against the backdrop of the COVID-19 pandemic. During May 2020, the authors examined intended vaccination in the next 12 months in relationship to demographic variables, healthcare attitudes, and personal COVID-19 experiences for two samples of adults--those who did not receive influenza vaccine during the prior 12 months, and those who did. Methods In May 2020, a cross-sectional online survey was conducted with a national US sample. Participants reported prior influenza vaccination (yes/no during prior 12 months) and anticipated vaccination (yes/no during next 12 months). Covariates included demographic characteristics (e.g., gender, race-ethnicity, political ideology), general beliefs (e.g., benefits of vaccines, altruistic attitudes), and COVID-19 health beliefs and experiences (COVID-19 worry and severity, perception of COVID-19 as a community threat, knowing someone with COVID-19). For each group, hierarchical multivariable logistic regression was conducted with intent to vaccinate as the outcome. Results Among participants (n = 3502), 47% did not receive influenza vaccine in the prior 12 months and 53% had; 25.5% of non-vaccinators and 91.9% of vaccinators intended future vaccination. For non-vaccinators, odds of intending vaccination was associated with race/ethnicity (Hispanics were more likely to intend than white-NH; AOR = 1.74; 95% CI = 1.23–2.4), greater perceived benefits of vaccination (AOR = 2.19; 95% CI = 1.88–2.54), and perception of COVID-19 as a community threat (AOR = 1.91; 95% CI = 1.49–2.45). For vaccinators, odds of intending vaccination was associated with age (AOR = 1.04; 95% CI = 1.03–1.05), race/ethnicity (Black-NH and Other-NH were less likely to intend than white-NH, AOR = 0.60; 95% CI = 0.36–0.999; and AOR = 0.45; 95% CI = 0.24–0.84, respectively), greater perceived benefits of vaccination (AOR = 1.88; 95% CI = 1.45–2.45) and greater perception of collective benefits of vaccines (AOR = 1.48; 95% CI = 1.15–1.90). Conclusions The COVID-19 pandemic may have served as a cue to action for influenza vaccination intention among some prior non-vaccinators whereas intention among prior vaccinators is more related to positive attitudes toward vaccination.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationSturm, L., Kasting, M. L., Head, K. J., Hartsock, J. A., & Zimet, G. D. (2021). Influenza vaccination in the time of COVID-19: A national US survey of adults. Vaccine, 39(14), 1921-1928. https://doi.org/10.1016/j.vaccine.2021.03.003en_US
dc.identifier.urihttps://hdl.handle.net/1805/25736
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.isversionof10.1016/j.vaccine.2021.03.003en_US
dc.relation.journalVaccineen_US
dc.rightsPublic Health Emergencyen_US
dc.sourcePublisheren_US
dc.subjectvaccinationen_US
dc.subjectinfluenza vaccinationen_US
dc.subjectCOVID-19en_US
dc.titleInfluenza vaccination in the time of COVID-19: A national U.S. survey of adultsen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Sturm2021Influenza.pdf
Size:
344.1 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: